Institute of Traditional Chinese Medicine in Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China.
Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, People's Republic of China.
Hereditas. 2023 Dec 15;160(1):39. doi: 10.1186/s41065-023-00303-x.
As an anticancer Chinese herbal medicine, the effective components and mechanism of Actinidia chinensis Planch (ACP, Tengligen) in the treatment of colon cancer are still unclear. In the present study, the integration of network pharmacology, molecular docking, and cell experiments was employed to study the effective mechanism of ACP against colon cancer.
The Venn diagram and STRING database were used to construct the protein-protein interaction network (PPI) of ACP-colon cancer, and further topological analysis was used to obtain the key target genes of ACP in colon cancer. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to visualize the related functions and pathways. Molecular docking between key targets and compounds was determined using software such as AutoDockTools. Finally, the effect of ACP on CT26 cells was observed in vitro.
The study identified 40 ACP-colon key targets, including CASP3, CDK2, GSK3B, and PIK3R1. GO and KEGG enrichment analyses found that these genes were involved in 211 biological processes and 92 pathways, among which pathways in cancer, PI3K-Akt, p53, and cell cycle might be the main pathways of ACP against colon cancer. Molecular docking verified that the key components of ACP could stably bind to the corresponding targets. The experimental results showed that ACP could inhibit proliferation, induce apoptosis, and downregulate the phosphorylation of PIK3R1, Akt, and GSK3B in CT26 cells.
ACP is an anti-colon cancer herb with multiple components, and involvement of multiple target genes and signaling pathways. ACP can significantly inhibit proliferation and induce apoptosis of colon cancer cells, which may be closely related to the regulation of PI3K/AKT/GSK3B signal transduction.
作为一种抗癌中草药,猕猴桃(ACP,藤梨根)治疗结肠癌的有效成分和机制仍不清楚。本研究采用网络药理学、分子对接和细胞实验相结合的方法,研究 ACP 抗结肠癌的有效机制。
利用 Venn 图和 STRING 数据库构建 ACP-结肠癌的蛋白质-蛋白质相互作用网络(PPI),并进一步进行拓扑分析,获得 ACP 治疗结肠癌的关键靶基因。采用基因本体论(GO)和京都基因与基因组百科全书(KEGG)富集分析可视化相关功能和通路。利用 AutoDockTools 等软件对关键靶标和化合物进行分子对接。最后,观察 ACP 对 CT26 细胞的体外作用。
研究确定了 40 个 ACP-结肠癌的关键靶标,包括 CASP3、CDK2、GSK3B 和 PIK3R1。GO 和 KEGG 富集分析发现,这些基因参与了 211 个生物学过程和 92 条通路,其中癌症通路、PI3K-Akt、p53 和细胞周期可能是 ACP 抗结肠癌的主要通路。分子对接验证了 ACP 的关键成分能够与相应的靶标稳定结合。实验结果表明,ACP 能够抑制 CT26 细胞的增殖,诱导细胞凋亡,并下调 PIK3R1、Akt 和 GSK3B 的磷酸化。
ACP 是一种多成分的抗结肠癌草药,涉及多个靶基因和信号通路。ACP 能显著抑制结肠癌细胞的增殖并诱导其凋亡,这可能与调节 PI3K/AKT/GSK3B 信号转导密切相关。